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ABSTRACT Stereoselective drug-channel interactions may help to elucidate the molecular basis of voltage-gated potas-
sium channel block by local anesthetic drugs. We studied the effects of the enantiomers of bupivacaine on a cloned human
cardiac potassium channel (hKvl.5). This channel was stably expressed in a mouse Ltk- cell line and studied using the
whole-cell configuration of the patch-clamp technique. Both enantiomers modified the time course of this delayed rectifier
current. Exposure to 20 ,uM of either S(-)-bupivacaine or R(+)-bupivacaine did not modify the activation time constant of the
current, but reduced the peak outward current and induced a subsequent exponential decline of current with time constants
of 18.7 ± 1.1 and 10.0 ± 0.9 ms, respectively. Steady-state levels of block (assessed with 250-ms depolarizing pulses to +60
mV) averaged 30.8 ± 2.5% (n = 6) and 79.5 ± 3.2% (n = 6) (p < 0.001), for S(-)- and R(+)-bupivacaine, respectively. The
concentration dependence of hKv1.5 inhibition revealed apparent KD values of 27.3 ± 2.8 and 4.1 ± 0.7 ,uM for S(-)-
bupivacaine and R(+)-bupivacaine, respectively, with Hill coefficients close to unity, suggesting that binding of one enanti-
omer molecule per channel was sufficient to block potassium permeation. Analysis of the rate constants of association (k) and
dissociation (I yielded similar values for / (24.9 s-1 vs. 23.6 s-1 for S(-)- and R(+)-bupivacaine, respectively) but different
association rate constants (1.0 x 106 vs. 4.7 x 106 M-1 s-1 for S(-)- and R(+)-bupivacaine, respectively). Block induced by
either enantiomer displayed a shallow voltage dependence in the voltage range positive to 0 mV, i.e., where the channel is
fully open, consistent with an equivalent electrical distance 5 of 0.16 ± 0.01. This suggested that at the binding site, both
enantiomers of bupivacaine experienced 16% of the applied transmembrane electrical field, referenced to the inner surface.
Both bupivacaine enantiomers reduced the tail current amplitude recorded on return to -40 mV and slowed their time course
relative to control, resulting in a "crossover" phenomenon. These data indicate 1) the charged form of both bupivacaine
enantiomers block the hKv1.5 channel after it opens, 2) binding occurs within the transmembrane electrical field, 3) unbinding
is required before the channel can close, 4) block of hKv1.5 channels by bupivacaine is markedly stereoselective, with the
R(+)-enantiomer being the more potent one, 5) this stereoselective block was associated with a 1.11 -kcal/mol difference in
binding energy between both enantiomers, and 6) the stereoselectivity derives mainly from a difference in the association rate
constants, suggesting that the S(-)-enantiomer is less likely to access the binding site in an optimal configuration.
INTRODUCTION
Bupivacaine is a long-acting and potent local anesthetic agent
widely used for regional anesthesia (Strichartz and Ritchie,
1987) that exhibits a high affity for the inactivated state of
Na+ channels (Clarkson and Hondeghem, 1985). Because it
contains a chiral carbon atom, the clinically used form is a
racemic mixture of S(-)-bupivacaine and R(+)-bupivacaine.
We have observed that inactivated state block of cardiac Na+
channels displays a moderate stereoselectivity, with R(+)-
bupivacaine being 1.6 times more potent than S(-)-bupiva-
caine, whereas the interactions of bupivacaine enantiomers
with the rested and the activated/open states were not stereo-
selective (Valenzuela et al., 1993).
Local anesthetics are useful probes of ion channel func-
tion and structure. Stereoselective interactions are espe-
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cially of interest because they can reveal three-dimensional
relationships between drug and channel with otherwise
identical biophysical properties. In addition, identification
of such stereospecific interactions may have practical con-
sequences. Indeed, in vivo studies have demonstrated that
the potency and duration of the anesthesia were equal or
even larger for S(-)-bupivacaine than the R(+)-enantiomer
(Luduena et al., 1972; Aberg, 1972; Aps and Reynolds,
1978). More important, the LD50 for R(+)-bupivacaine was
-30-40% lower than for S(-)-bupivacaine (Luduena et
al., 1972; Aberg, 1972). Although the higher potency of
R(+)-bupivacaine to inhibit INa (Valenzuela et al., 1993)
could explain in part its higher cardiotoxicity over S(-)-
bupivacaine, several studies have also shown a prolongation
of the Q-Tc interval of the electrocardiogram (ECG) in
anesthetized dogs (Avery et al., 1984; Wheeler et al., 1988;
Solomon et al., 1990) and human volunteers (Scott et al.,
1989) receiving high doses of bupivacaine. In some cases,
this was accompanied by torsades de pointes (Kasten and
Martin 1985). These results suggest that the cardiotoxicity
of bupivacaine also involves block of K+ channels.
As previously described for other local anesthetic agents
(Strichartz and Ritchie, 1987), racemic bupivacaine blocks
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several cardiac K+ currents, including the transient outward
current (ITO) and the delayed outward K+ current (IK)
(Castle, 1990; Sainchez-Chapula, 1988; Courtney et al.,
1988). Recently, a fast activating outward potassium current
has been described in rat atrial myocytes (Boyle and Ner-
bonne, 1991), neonatal canine ventricular myocytes (Jeck
and Boyden, 1992), and human atria (Fedida et al., 1993;
Wang et al., 1993). The properties of this channel are most
similar to those reported for the cloned cardiac hKvl.5
channel (Philipson et al., 1991; Tamkun et al., 1991; Sny-
ders et al., 1993; Fedida et al., 1993). The hKvl.5-like
current is involved in the control of the cardiac action
potential duration (Wang et al., 1993) and, thus, represents
a potential molecular target for drugs that prolong the car-
diac action potential duration (Roberds et al., 1993).
Expression of this channel in a system without contami-
nating conductances allows for a detailed analysis of drug-
channel interactions, which forms a necessary basis to elu-
cidate structure-function relationships. The goals of the
present study were 1) to characterize the voltage-dependent
effects of bupivacaine enantiomers on hKvl.5, 2) to deter-
mine the kinetic state of the channel for which the enanti-
omers exhibit their highest affinity, and 3) to determine the
basis for the possible stereoselectivity of the interaction
between bupivacaine enantiomers and the hKv1.5 channel.
A preliminary report of the present study has been published
in abstract form (Valenzuela et al., 1994).
MATERIALS AND METHODS
Cell culture and solutions
The method to establish hKv1.5 expression in a clonal mouse Ltk--cell line
has been described previously (Snyders et al., 1992, 1993). Transfected
cells were cultured in DMEM supplemented with 10% horse serum and
0.25 mg/ml G418, under a 5% CO2 atmosphere. The cultures were passed
every 3-5 days, using a brief trypsin treatment. Before experimental use,
subconfluent cultures were incubated with 2 ,uM dexamethasone for 24 h.
The cells were removed from the dish with a rubber policeman, a procedure
that left the vast majority of the cells intact. The cell suspension was stored
at room temperature (20-22°C) and used within 12 h for all experiments
reported here.
The intracellular pipette filling solution contained (in mM): K-aspartate
80, KCI 50, KH2PO4 10, MgATP 3, HEPES 10, EGTA 5, and was adjusted
to pH 7.25 with KOH. The bath solution contained (in mM): NaCl 130,
KCI 4, CaCl2 1.8, MgCI2 1, HEPES 10, and glucose 10, and was adjusted
to pH 7.35 with NaOH. Both bupivacaine enantiomers (a gift from Astra
Hassle AB, Molndal, Sweden) were dissolved in distilled deionized water
to yield stock solutions of 10 mM from which further dilutions were made
to obtain the desired final concentration.
Electrical recording
Experiments were performed in a small volume (0.5 ml) bath mounted on
the stage of an inverted microscope (Nikon model TMS, Garden City, NY)
perfused continuously at a flow rate of 0.5-1.0 ml/min. The hKvl .5
currents were recorded at room temperature (20-22°C) using the whole-
cell voltage-clamp configuration of the patch-clamp technique (Hamill et
al., 1981) with an Axopatch-IC patch-clamp amplifier (Axon Instruments,
Foster City, CA). Currents were filtered at 2 kHz (four-pole Bessel filter),
QS/16S computer for subsequent analysis. Data acquisition and command
potentials were controlled by the pClamp 5.5.1. software (Axon Instru-
ments).
Micropipettes were pulled from borosilicate glass capillary tubes
(Narishige, GD-1, Tokyo, Japan) on a programmable horizontal puller
(Sutter Instrument Co., San Rafael, CA) and heat-polished with a micro-
forge (Narishige). When filled with the intracellular solution and immersed
into the bath (external) solution, the pipette tip resistance ranged between
1 and 3 Mfl. The micropipettes were gently lowered onto the cells to obtain
a gigaohm seal (16 + 6 GQ7) after applying suction. After seal formation,
cells were lifted from the bottom of the perfusion bath and the membrane
patch was ruptured with brief additional suction. The capacitive transients
elicited by symmetrical 10-mV steps from -80 mV were recorded at 50
kHz (filtered at 10 kHz) for subsequent calculation of capacitative surface
area, access resistance, and input impedance. Thereafter, capacitance and
series resistance compensation were optimized, and 80% compensation of
the effective access resistance was usually obtained.
Pulse protocol and analysis
After control data were obtained, bath perfusion was switched to drug-
containing solution. Drug infusion or removal was monitored with test
pulses from -80 to +30 mV, applied every 30 s until steady-state was
obtained (within 10-15 min). The holding potential was maintained at -80
mV. The cycle time for any protocol was 10 s to avoid accumulation of
block or incomplete deactivation of the current.
The protocol to obtain current-voltage (I-V) relationships and activation
curves consisted of 250-ms pulses that were imposed in 10-mV increments
between -80 and +60 mV, with additional interpolated pulses to yield
5-mV increments between -30 and +10 mV, i.e., the activation range of
hKvl.5 (Snyders et al., 1993). The "steady-state" I-V relationships were
obtained by measuring the current at the end of the 250-ms depolarizations.
Between -80 and -40 mV, only passive linear leak was observed and
least-squares fits to these data were used for passive leak correction.
Deactivating "tail" currents were recorded at -40 mV. The activation
curve was obtained from the tail current amplitude immediately after the
capacitive transient or from the amplitude of the exponential fit to its time
course. Both procedures gave similar results in controls. Measurements
were done using the clampfit program of pClamp 5.5.1. and by a custom-
made analysis program.
Activation curves were fitted with a Boltzmann equation:
y = 1/[1 + exp( - )(E
-Eh)/s], (1)
in which s represents the slope factor, E the membrane potential, and Eh the
voltage at which 50% of the channels are open. The time course of tail
currents and the slow inactivation were fitted with the sum of exponentials.
The activation kinetics was determined with the dominant time constant of
activation approach in which a single exponential was fitted to the latter
50% of activation (White and Bezanilla, 1985; Snyders et al., 1993;
Valenzuela et al., 1994). The curve-fitting procedure used a nonlinear
least-squares (Gauss-Newton) algorithm; results were displayed in linear
and semilogarithmic format, together with the difference plot. Goodness of
fit was judged by the x2 criterion and by inspection for systematic non-
random trends in the difference plot.
A first-order blocking scheme was used to describe drug-channel inter-
action. The apparent affinity constant, KD, and Hill coefficient, nH, were
obtained from fitting of the fractional block, f, at various drug concentra-
tions [D]:
f = 1/{1 + (KD/[D])nH}, (2)
and apparent rate constants for binding (k) and unbinding (1) were obtained
from solving
k X [D] + 1/B (3a)
sampled at 4 kHz, and stored on the hard disk of a Hewlett-Packard Vectra
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Voltage dependence of block was determined as follows: leak-corrected
current in the presence of drug was normalized to matching control to yield
the fractional block at each voltage (f = I - Idrug/Icontrol) The voltage
dependence of block was fitted to
f= [D]/{[D] + KD X exp( - 8zFE/RT)}, (4)
where z, F, R, and T have their usual meaning, 6 represents the fractional
electrical distance, i.e., the fraction of the transmembrane electrical field
sensed by a single charge at the receptor site and KD represents the apparent
dissociation constant at the reference potential (0 mV).
Statistical Methods
Results are expressed as mean ± SEM. Direct comparisons between mean
values in control conditions versus mean values in the presence of drug for
a single variable were performed by a paired Student's t-test. ANOVA was
used to compare more than two groups. Student's t-test was also used to
compare two regression lines. Differences were considered significant if
p < 0.05.
RESULTS
Dose-dependent and reversible block by R(+)-
and S(-)-bupivacaine
The top panels of Fig. 1, A and B show superimposed
tracings of potassium current through hKv1.5 channels ex-
pressed in mouse Ltk- cells after the application of 250-ms
depolarizing pulses from -80 mV to different test poten-
tials between -60 and +60 mV. Under control conditions,
the hKv1.5 current rose rapidly with a sigmoidal time
course to a peak and then declined slowly (slow and partial
inactivation). Outward tail currents were observed upon
repolarization to -40 mV. Activation time constants ranged
from 25.8 ± 1.8 ms at -10 mV (n = 23) to 2.1 ± 0.2 ms
at +60 mV (n = 23), as described previously (Philipson et
al., 1991; Snyders et al., 1992, 1993). Induction of block
after switching of perfusion with each enantiomer pro-
gressed with a time constant of 3-4 min, which was about
5 times slower than the effect of changing extracellular K+
concentration at similar flow rates. This delay suggested an
intramembrane or intracellular site of action and, therefore,
10-15 min of equilibration were allowed before assessment
of drug effects.
The middle panels of Fig. 1, A and B illustrate the
differential effectiveness of either enantiomer at an identical
concentration (20 ,uM). R(+)-bupivacaine displayed a
higher potency than S(-)-bupivacaine to inhibit the hKv1.5
current. Both enantiomers not only reduced the current
amplitude but also altered the time course of the current
during depolarization, without modifying the initial activa-
tion time course of the current. The drug-induced acceler-
ated decline of hKv1.5 current to the reduced steady-state
level proceeded with time constants of 18.7 ± 1.1 and
10.0 ± 0.9 ms for this concentration of the S(-)- and R(+)-
enantiomers, respectively. At the end of a 250-ms step to
+ 60 mV, this concentration of S(-)-bupivacaine and
R(+)-bupivacaine reduced the hKvl.5 current by 31 ± 2%
(n = 5) and 79 ± 3% (n = 5) (p < 0.001), respectively. The
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FIGURE 1 Effects of S(-)-bupivacaine and R(+)-bupivacaine on
hKv1.5 currents. Currents are shown for depolarizations from -80 mV to
voltages between -60 and +60 mV in steps of 20 mV. Tail currents were
obtained on return to -40 mV. (A) Effects of S(-)-bupivacaine (20 JIM)
on hKv1.5. Traces were obtained in control conditions (top), in the pres-
ence of 20 jiM S(-)-bupivacaine (middle), and after 20 min of wash out
(bottom). Cell capacitance, 20 pF. Data filtered at 2 kHz (four-pole Bessel)
and digitized at 10 kHz; additional digital filtering at 1 kHz. (B) Effects of
R(+)-bupivacaine (20 ,uM) on hKv1.5. Traces were obtained in control
conditions (top), in the presence of 20 ,uM R(+)-bupivacaine (middle), and
after 20 min of wash out (bottom). Cell capacitance, 22 pF. Data filtered at
2 kHz (four-pole Bessel) and digitized at 10 kHz; additional digital filtering
at 1 kHz.
reversibility of these effects are illustrated by the bottom
panels of Fig. 1, A and B. The amplitude of the current was
restored to 95 and 88%, respectively, after 20 min perfusion
of the cells with drug-free solution. On average, the current
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was restored to 88 ± 2.1% (n = 50) of its initial control
value after a 20-min washout.
Fig. 2 shows the concentration dependence of S(-)-
bupivacaine and R(+)-bupivacaine block of hKvl.5. To
allow for the slower kinetics with lower concentrations (see
below), we used suppression of current at the end of 250-ms
depolarizations to +60 mV as an index of steady-state
inhibition (fractional block = 1
-Idrug/Icontrol). At all con-
centrations tested (0.3-100 ,uM), the degree of hKvl.5
block induced by R(+)-bupivacaine was significantly
greater than that induced by S(-)-bupivacaine (p < 0.001).
Thus, in the presence of 10 ,uM S(-)-bupivacaine and
R(+)-bupivacaine, hKv1.5 inhibition averaged 29 ± 3%
(n = 4) and 62 ± 6% (n = 9), respectively. A nonlinear
least-squares fit of the concentration-response equation (Eq.
2, see Materials and Methods) to the individual data points
yielded an apparent KD of 27.3 + 2.8 and 4.1 + 0.7 ,uM
(p < 0.01) for S(-)-bupivacaine and R(+)-bupivacaine,
respectively. The Hill coefficients were 1.22 ± 0.22 and
0.85 ± 0.10 (p > 0.05) for S(-)-bupivacaine and R(+)-
bupivacaine, respectively. The dashed line in Fig. 2 illus-
trates a fit of the same data with the Hill coefficient fixed at
1. The apparent KD values obtained for both bupivacaine
enantiomers were similar to those obtained without con-
straining the Hill coefficients. These results suggest that
binding of a single bupivacaine molecule is sufficient to
block the hKvl.5 channel.
Voltage-dependent block by bupivacaine of
hKv1.5 channels
Fig. 3 A shows the effects of 50 ,uM S(-)-bupivacaine on
the steady-state current-voltage (I-V) relationship for the
hKv1.5 channel. The I-V relationship under control condi-
tions was quasi-linear for depolarizations positive to +10
1.0
.e 0.8
0
_ 0.6
0
= 0.4
L 0.2 * S(-)Bupivacaine
KD = 27.3 ,uM
0.0 J
0.0010.01 0.1 1 10 100 1000
Drug [pM]
FIGURE 2 Concentration dependence of S(-)-bupivacaine- and R(+)-
bupivacaine-induced block of hKvl.5. Reduction of current (relative to
control) at the end of depolarizing steps from -80 mV to +60 mV was
used as index of block. Data are mean ± SEM of a total of 51 experiments.
The solid line represents the fit of the experimental data to the equation:
1/{1 + (KD/[D])nH}. For comparison, the dashed line represents the fit for
a Hill coefficient (nH) of 1.
A.
4 1.0*
1-
LA
=0.5
B.
1.0
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FIGURE 3 Voltage dependence of hKv1.5 block by S(-)-bupivacaine
(50 ,uM). (A) Current-voltage relationship (250 ms isochronal) in control
conditions (0) and in the presence of 50 ,uM S(-)-bupivacaine (0). (B)
Relative current expressed as IS(-)-bupivacaine/Icontrol from data shown in A.
The dashed line represents the activation curve for this experiment. Block
increased steeply between -20 and 0 mV (A), which corresponds to the
voltage range of activation of hKv1.5. For membrane potentials positive to
0 mV, a continued but more shallow voltage dependence was observed (0)
that represents the effect of the membrane electrical field on the interaction
between S(-)-bupivacaine and the hKv1.5 channel. This voltage depen-
dence was fitted ( ) with Eq. 4 (see Materials and Methods) and yielded
8= 0.16.
mV, whereas the sigmoidicity between -30 and +10 mV
reflects the voltage-dependence of channel gating (Snyders
et al., 1993). In the presence of 50 AM S(-)-bupivacaine,
the curve displayed a downward curvature at test potentials
positive to 0 mV, which suggested that this enantiomer
produced more extensive block at very positive depolariza-
tions. To quantitate the voltage dependence of hKvl.5
block, the relative current 'drug/acontrol was plotted as a
function of membrane potential (Fig. 3 B). Human Kvl.5
block increased steeply between -30 and 0 mV (open
triangles), which corresponded to the voltage range of chan-
nel opening (dashed line). Between 0 and +60 mV (closed
circles), block continued to increase but with a shallower
voltage dependence, although all channels were open over
this voltage range. These results suggested that S(-)-bupiv-
acaine preferentially bound to the open state of the hKvl.5
channel. Fig. 4 illustrates that R(+)-bupivacaine induced a
similar downward curvature of the steady-state I-V relation-
ship at positive potentials, as well as a biphasic voltage-
dependence of hKv1.5 block. The total voltage-dependency
of block induced by both bupivacaine enantiomers appeared
to be composed of a steep phase coinciding with channel
activation (Figs. 3 B and 4 B, dashed lines) and a shallower
phase at membrane potentials positive to 0 mV. Thus, the
overall mechanism appears similar, but the effects occurred
at lower concentrations compared to S(-)-bupivacaine.
It is unlikely that the shallow voltage dependence of
block observed at membrane potentials positive to 0 mV
was due to channel gating, because hKv1.5 activation had
reached saturation over this voltage range with time con-
stants of 10 ms or less. Bupivacaine is a weak base and has
a tertiary amine group with pK. = 8.1, so that at the
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FIGURE 4 Voltage dependence of hKv1.5 block by R(+)-bupivacaine
(20 ,tM). (A) Current-voltage relationship (250 ms isochronal) in control
conditions (@) and in the presence of 20 ,tM R(+)-bupivacaine (0). (B)
Relative current expressed as IR(+)-LtivacaincIIcontro1 from data shown in A.
The dashed line represents the activation curve for this experiment. Block
increased steeply between -20 and () mV (A), which corresponds to the
voltage range of activation of hKvI.5. For membrane potentials positive to
0 mV, a continued but more shallow voltage dependence was observed (0)
that represents the effect of the membrane electrical field on the interaction
between R(+)-bupivacaine and the hKv1.5 channel. This voltage depen-
dence was fitted ( ) with Eq. 4 (see Materials and Methods) and yielded
8= 0.16.
intracellular pH of 7.2, it is present predominantly in its
charged form. Thus, the shallow component in the voltage
dependence of block that appears at membrane potentials
positive to 0 mV could result from the influence of the
transmembrane electrical field on the interaction between
cationic bupivacaine and the channel receptor. If bupiva-
caine reaches the receptor from the inside, block is expected
to increase in a voltage-dependent manner. Indeed, the
percentage of block induced by 50 ,uM S(-)-bupivacaine
significantly increased from 59.0 5.6% at 0 mV to 69.5 +
3.7% at +60 mV (n = 5; p < 0.01). With 20 ,uM R(+)-
bupivacaine, block increased from 72.4 + 3.6% at 0 mV to
79.5 + 3.2% at +60 mV (n = 5; p < 0.01). In both cases,
the voltage dependence of block observed in this range of
membrane potentials (between 0 and +60 mV) was de-
scribed by a Boltzmann relationship based on the Woodhull
model (Eq. 4 in Materials and Methods). The parameter in
this equation represents the fractional electrical distance,
i.e., the fraction of the membrane electrical field sensed by
a single charge at the receptor site (Woodhull, 1973). The
solid lines in Figs. 3 B and 4 B represent the fits of this
Boltzmann equation to the data points positive to 0 mV
(solid symbols). The latter restriction was required to quan-
tify this effect independent from the voltage dependence of
channel opening. Using this analysis, we obtained a value of
0.16 for the fractional electrical distance (6) for the two
experiments shown. In the presence of 50 ,uM S(-)-bupiv-
acaine, the value averaged 0.164 ± 0.002 (n = 6).
Similarly, the averaged value obtained for R(+)-bupiva-
caine (20 ,uM) was 0.168 0.007 (n = 6), a value that was
not significantly different from 6 obtained for S(-)-bupiv-
acaine (p > 0.05).
Concentration dependence of time course of
channel block
If both bupivacaine enantiomers can only access to their
binding site when the channel is open, then the inhibition of
the potassium current would only develop after the channels
start to open, and development of block should be conspic-
uous if the blocking rate is slower than the opening rate. On
the other hand, if the blocking rate exceeded that of channel
opening, or if bupivacaine enantiomers blocked other states
of the channel, then the current recorded in the presence of
drug would be expected to be scaled down. Fig. 5, A and B
show superimposed recordings of 250-ms depolarizations
from -80 to +60 mV under control conditions and in the
presence of three different concentrations of S(-)-bupiva-
caine and R(+)-bupivacaine, respectively. Under control
conditions, the potassium current reached its maximum
level within 10 ms and then declined slowly, with a time
constant of 160 ms. In the presence of S(-)-bupivacaine
and R(+)-bupivacaine, the peak was decreased in a concen-
tration-dependent manner. In both cases, the subsequent
time course displayed an additional rapid exponential com-
ponent superimposed on the slow inactivation. As illus-
trated in Fig. 5, A and B, the time course of this decline was
concentration-dependent. The time constants of the fast
component in the presence of 20, 50, and 100 ,uM of
S(-)-bupivacaine were 20, 17, and 7 ms, respectively.
These time constants (TB) were at least 8 times faster than
those of the (partial) slow inactivation observed under con-
trol conditions. Therefore, they were taken as an approxi-
mation of bimolecular drug-channel interaction kinetics,
similar to the approach used previously for the interaction of
quinidine with this channel (Snyders et al., 1992). Fig. 5 C
shows the plot of I/TB vs. S(-)- and R(+)-bupivacaine
concentration for data obtained in 40 experiments. The
straight lines are the least-squares fit to the relation 1I/TB =
kX [D] + 1. Slope and intercept for the fitted relation yielded
apparent association rate constants (k) of (1.03 ± 0.09) X
106 M-l s-' and (4.71 + 0.45) X 106 M-l S-1 for S(-)-
bupivacaine and R(+)-bupivacaine, respectively (p <
0.01). The dissociation rate constants (1) resulted to be
similar for both bupivacaine enantiomers, being 24.3 + 6.4
and 23.6 + 13.6 s- 1 for S(-)-bupivacaine and R(+)-
bupivacaine, respectively (p > 0.05). Thus, the dissociation
rate constants were similar for both enantiomers, and the
data suggest that the stereoselectivity derives from the dif-
ferences in the binding rate constants.
Time course of tail currents
After a depolarizing step from -80 to +60 mV, the potas-
sium currents deactivated completely on return to -40 mV
with a time constant of 46 + 4 ms (n = 10). This time
constant reflects mainly the virtually irreversible closing of
the channel. If both S(-)- and R(+)-bupivacaine bind only
to the open state of hKvl.5 channels, then the dissociation
of the enantiomers from the blocked channel should result
Biophysical Journal422
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FIGURE 5 Kinetics of block induction by S(-)- and R(+)-bupivacaine. (A) Superimposed traces for steps from -80 to +60 mV and tail currents recorded on
return to -40 mV under control conditions (0) and in the presence of 20, 50, and 100 pM S(-)-bupivacaine. (B) Superimposed traces for steps from -80 to +60
mV and tail currents recorded on return to -40 mV under control conditions (0) and in the presence of 1, 10, and 20 ,uM R(+)-bupivacaine. In the presence of
both S(-)- and R(+)-bupivacaine, the current activated initially as under control conditions but reached a lower peak and subsequently declined more quickly.
(C) Rate of block as a function of drug concentration. The time constant of S(-)- and R(+)-bupivacaine-induced fast component (TB) was obtained from
biexponential fits to the falling phase of the tracings shown in A and B. The inverse of TB was plotted versus drug concentration. For a first-order blocking scheme,
a linear relation is expected: 1i/TB = kX[D] + 1. The solid lines represent the linear fits for TB of the fast component observed in the presence of S(-)- and
R(+)-bupivacaine, from which the apparent binding and unbinding rate constants were obtained. Note that the unbinding rate constants (1) obtained from the
y-intercept were similar for both enantiomers (24 s-1), whereas the slope of the line (binding rate constant, k) were different, being faster in the presence of
R(+)-bupivacaine (4.7 X 106 vs. 1.0 X 106 M-1 s-1).
in an open channel (which subsequently could close).
Blocked channels are not conducting, and the conversion to
open channels, therefore, should result initially in a rising
phase of the tail current. Subsequently, the tail current
should display a slower decline because some fraction of the
open channels become blocked again, rather than closing
irreversibly (Armstrong 1971; Choi et al., 1993; Snyders et
al., 1992). Fig. 6 A shows the superposition of the tail
currents obtained at -40 mV after 250-ms depolarization to
+60 mV under control conditions and in the presence of 50
,uM S(-)-bupivacaine. After exposure to this enantiomer,
the initial amplitude of the tail current was reduced and the
tail current displayed a rising phase reaching a peak after
10.0 ± 5.0 ms. The subsequent decline of the tail current
was slower than in control conditions (44 ± 2 vs. 223 ± 45
A.
Control
< \ S(-)-Bupi
a. (50 pM)
0
0
100 ms
B.
Control
R(+)-Bupi
< r-
~(10 PM)4:
0
0
100 ms
FIGURE 6 Tail current crossover. (A) Currents recorded in control con-
ditions and in the presence of 50 ,uM S(-)-bupivacaine. (B) Currents
recorded in control conditions and in the presence of 10 ,uM R(+)-
bupivacaine. Tail currents were obtained at -40 mV after a 250-ms
depolarizing pulse to +60 mV. Arrow shows the crossover of tracings
recorded in the presence of S(-)-bupivacaine or R(+)-bupivacaine with
those recorded under control conditions.
ms, in control and in the presence of 50 ,tM S(-)-bupiva-
caine, respectively; n = 5), resulting in a "crossover" phe-
nomenon. Similar modifications of the time course of the
tail currents were observed with 10 ,uM R(+)-bupivacaine
(Fig. 6 B). The peak tail current was obtained after 14 ± 4
ms, and the decay time constants increased from 45 ± 3 ms
in control to 260 ± 73 ms in the presence of R(+)-bupiva-
caine, which again resulted in a "crossover" phenomenon.
These results supports an open-channel interaction between
both bupivacaine enantiomers and hKv1.5 channels.
Open channel block model
The experimental results obtained in this study were inter-
preted and simulated using a simplified kinetic state dia-
gram similar to that used for the related Shaker and RCK1
channels (Koren et al., 1990; Zagotta and Aldrich 1990) and
was used previously to describe block of the hKvl.5 chan-
nel by quinidine (Snyders et al., 1992):
4a 3a 2a a k X [D]
C=C=C=C=O OB
21 3( 4, 1
To incorporate the interaction of S(-)-bupivacaine and
R(+)-bupivacaine into this diagram, we assumed that either
enantiomer binds only to the open state of the channel.
Because the activation process is fast at potentials positive
to 0 mV, this system is functionally reduced to a three-state
model (I r± 0 OB). In the presence of S(-)-bupivacaine
and R(+)-bupivacaine, the inactivation became biexponen-
C.
4001
i/Tb
s-i
200 -
0-
20 50
Drug [pM]
100
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tial, as expected for this model. The drug-induced extra
component of inactivation had a time constant (T) that was
much faster than the slow inactivation of the current under
control conditions. Thus, this fast T can be considered to
represent the interaction of bupivacaine enantiomers (B)
with the open state (0) of hKvl.5 channel (0 2± OB), TB =
1/(kX [D] + 1). Fig. 7 shows the mathematical simulation of
the effects of 50 ,uM S(-)- and 10 ,tM R(+)-bupivacaine,
based on this open-channel block model, reproducing the
experimental observed changes in time course during depo-
larization and deactivating tails (Figs. 1, 5, and 6). As it can
be observed, a model that only assumes an open channel
interaction reproduces the experimental data reasonably
well.
DISCUSSION
4a 3a 2a a k'"
A. ZC Z4t Z O . OSB
2( 3 4
Control
S(-)-Bupi
\ (1 0 pM)
OZ\IfD. .;(50t--DUpMi
(50 pM) <
.......................................................
0 250 500
4a 3a 2a a k 'BE c -"C
-* -1"C :;:tC -lZ O ORB
2 3 4
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R(+)-Bupi
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FIGURE 7 Mathematical modeling of S(-)-bupivacaine and R(+)-
bupivacaine interactions with hKvl.5 channels. (A) Simulation of S(-)-
bupivacaine-hKvI.5 interaction. The open-channel block model was used
with the following rate constants: at +60 mV, a = 400 s-', B = 1 s-', k
= 1.0 ,uM-' s-', and l = 24 s-'; at -40 mV, a = 0.1 s-', , = 7 s-1,
k = 0.5 ,uM-' s- and = 45 s--l. For depolarization, simulations for
control and for 10 and 50 ,uM S(-)-bupivacaine are displayed; for the tails,
control and 50 ,uLM S(-)-bupivacaine are shown. (arrow) Crossover.
Currents for step and tail were scaled to reflect the difference in driving
force. (B) Simulation of R(+)-bupivacaine-hKvl.5 interaction. The open-
channel block model was used with the following rate constants: at +60
mV, a 400s )3 I s-', k = 4.7 iM- s- ', and = 24 s;at-40
mV, a 0.1 s-, 3= 7 s-', k = 3.2 ,uM- s-1 and I = 45 s-'. For
depolarization, simulations for control and for 1 and 10 ,uM R(+)-bupiv-
acaine are displayed; for the tails, control and 10 ,uM R(+)-bupivacaine are
shown. (arrow) Crossover. Currents for step and tail were scaled to reflect
the difference in driving force. In this model, we omitted for simplicity the
slow and partial inactivation and therefore this process was not reproduced
by the mathematical simulation shown in this figure.
In the present study, we have analyzed the interaction be-
tween S(-)- and R(+)-bupivacaine with human cardiac
Kv1.5 channels expressed in a stable cell line (Ltk-). The
main conclusions of the present paper are as follows: 1) the
charged form of both bupivacaine enantiomers blocks the
hKvl.5 channel after it opens; 2) binding occurs within the
transmembrane electrical field; 3) unbinding is required
before the channel can close; 4) bupivacaine-induced block
of hKvl.5 channels is markedly stereoselective, with R(+)-
bupivacaine being sevenfold more potent than S(-)-bupi-
vacaine; 5) this stereoselective block was associated with a
1.11-kcal/mole difference in binding energy between both
enantiomers; and 6) the stereoselectivity derives mainly
from a difference in the association rate constants, which
suggests that S(-)-bupivacaine is less likely to access the
binding site in an optimal configuration.
Time-dependent interactions between
bupivacaine enantiomers and hKv1.5 channels
S(-)-bupivacaine and R(+)-bupivacaine did not modify the
time course of activation, but induced an initial fast decline
of the hKv1.5 current during depolarization (see Fig. 1). The
time course of this fast decline (TB) was concentration-
dependent and was taken as an index of the binding process
of the drug. In the present experiments, R(+)-bupivacaine
was sevenfold more potent to block hKvl.5 channels than
S(-)-bupivacaine, which indicated that the blockade pro-
duced by bupivacaine was stereoselective. These data are
consistent with an open-channel block mechanism in which
both bupivacaine enantiomers only access their binding site
when the channel is opened and with a slower blocking rate
than the opening rate of the channel. Moreover, mathemat-
ical modeling assuming the interaction of each enantiomer
only with the open state of the channel, reproduced fairly
well the experimental data (see Fig. 7). At lower depolar-
izations, activation of hKvl.5 is much slower. The rate of
activation at 0 mV is comparable with the blocking rate that
would preclude to observe a distinct drug-induced decline
of current. This was indeed the case for the tracings at -20
and 0 mV in Fig. 1. Similarly, it was not possible to extract
reliable rate constants at low drug concentrations because
the time course of block became similar to that of slow
inactivation. Therefore, we did not include data obtained in
the presence of low concentrations of S(-)-bupivacaine
(below 20 ,uM) and R(+)-bupivacaine (below 10 ,uM) in
Fig. 5. The apparent binding and unbinding rate constants
I --I~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
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for S(-)-bupivacaine were calculated to be k = 1.0X 106
M-1 s-1 and 1 = 24.9 s-1, whereas for R(+)-bupivacaine
these rate constants were k = 4.7X 106 M-1 s-1 and 1 =
23.6 s-1, respectively. From these rate constants the appar-
ent affinity (KD = I/k) is estimated to be 5.0 and 24.9 ,uM
for (R+) and S(-)-bupivacaine, respectively. These esti-
mates are in good agreement with the values obtained from
steady-state suppression of the hKvl.5 current (4.1 and 27.3
,kM). This agreement between both independent methods to
estimate the affinity further supports the open-channel block
model used to derive the rate constants. It is of interest to
note that bupivacaine-induced block of nerve and cardiac
Na+ channels is also stereoselective. In cardiac Na+ chan-
nels, the higher potency of the R(+)-enantiomer was also
related to a faster association rate constant compared to the
S(-)-bupivacaine (Wang, 1990; Valenzuela et al., 1993).
Open channel block not only modifies the time course of
the current during depolarization, but can also influence the
time course of the deactivating currents (Follmer et al.,
1992; Snyders et al., 1992; Choi et al., 1993, Carmeliet,
1993). Under control conditions, channel deactivation upon
repolarization is fast and virtually irreversible (4B >> a).
However, if a large fraction of channels is blocked by either
bupivacaine enantiomer during the preceding depolarization
and if the unbinding rate (1) is fast enough, then the tail
current may display a rising phase that will reflect the
unblocking process. Subsequently, channels reach the open
state and may be blocked again before they eventually
deactivate. This process will be reflected by a slower time
course of the tail current (Fig. 6). The mathematical model
based on the experimentally derived rate constants predicted
both effects: 1) a rising phase, and 2) a slower time course
of deactivation, resulting in the "crossover" phenomenon
(Fig. 7), as observed in the records shown in Figs. 5 and 6.
These data further support the proposed interaction of both
enantiomers with the open state of the hKvl.5 channel.
Voltage dependence of bupivacaine block
Figs. 3 B and 4 B show that block of hKvl.5 channels
induced by S(-)-bupivacaine and R(+)-bupivacaine was
voltage-dependent, reaching a higher degree of block at
more positive than at more negative membrane potentials.
These results are consistent with the proposed open channel
block mechanism, because the probability of opening in-
creases at more positive membrane potentials. The voltage
dependence of block produced by both bupivacaine enanti-
omers consisted of two different phases: a steep one, which
coincides with the range of membrane potentials of channel
activation (-30 and 0 mV) and a shallower one, observed at
membrane potentials positive to 0 mV. Bupivacaine is a
weak base with a pK. of 8.1, which indicates that at the
intracellular pH of 7.2, most bupivacaine is present in its
charged form (88.8%). The access of the hydrophilic form
of the drug to the receptor requires a hydrophilic pathway
nium block of various potassium channels (Armstrong,
1971; French and Shoukimas, 1981; Yellen et al., 1991) as
well as for quinidine block of these hKv1.5 channels (Sny-
ders et al., 1992). This mode of access requires that the
charged drug moves into the electrical membrane field from
the inside, so that membrane depolarization will promote
entry of the cationic form into the channel. If a drug has a
high affinity for activated (open) channels, the voltage de-
pendence of channel activation superimposes on the intrin-
sic voltage dependence of drug binding because channel
activation makes the receptor available. Therefore, the total
voltage dependency of open channel block is composed of
a steep phase over the range of membrane potentials at
which the channel activates and a shallower phase over the
voltage range where al-l channels are open. The latter re-
flects the additional effect of the electrical field on the
interaction between the charged drug and the channel, as is
the case of bupivacaine enantiomers. From the shallow
voltage dependence, we obtained a fractional electrical dis-
tance (6) of 0.16 for both enantiomers. Not only is this result
consistent with binding in the open ion channel, but the
identical value also supports the assumption that both en-
antiomer bind at the same site in the channel.
Putative receptor site for bupivacaine on hKv1.5
channels
In Shaker channels, residues at the innermost turn of the
P-loop (connecting S5 and S6) as well as those located at
the putative S6 have been implicated in the binding of
quaternary ammonium derivatives (Yellen et al., 1991). The
electrical distance observed for bupivacaine enantiomers in
this study is very similar to the values obtained for internal
tetraethylammonium (TEA) block (6 = 0.16) of Shaker
channels (Yellen et al., 1991; Choi et al., 1993) and for
quinidine block of hKv1.5 channels (8 = 0.19) (Snyders et
al., 1992). Therefore, these results are consistent with a
common binding site for TEA, antiarrhythmic drugs and
local anesthetics in the internal mouth of the channel. How-
ever, because both bupivacaine and quinidine are very hy-
drophobic molecules (logP 4.0 and 2.4, respectively)
(Snyders et al., 1992), it is likely that the binding of these
drugs to the hKvl.5 channel is influenced by hydrophobic
residues in the channel, as was described recently for alkyl-
TEA derivatives in Shaker channels (Choi et al., 1993).
Hydrophobic interaction have also been suggested to ex-
plain the differences in hKv1.5 block between clofilium,
tetrapentylammonium, quinidine, and quinine (Snyders et
al., 1992).
Although the results for bupivacaine indicate a stereo-
selective interaction with the hKvl.5 pore, open channel
block of a cardiac transient outward current was not stere-
oselective (Castle, 1990). The molecular identity of this
channel has not yet been established, but Kv1.4 and Kv4.2
are potential candidates. The high degree of sequence con-
(Hille, 1977), as has been proposed for quaternary ammo-
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channels (Pongs, 1992) can explain the similar mechanism
of block. However, more subtle differences may be respon-
sible for isoform-specific differences in drug binding.
The values for the apparent dissociation constant (KD)
can be converted into apparent binding energies (AG) rela-
tive to a 1 M standard concentration using the relation:
AG = - RT X ln[lM/KD],
where R is the universal gas constant and T is the absolute
temperature. The free energy indicates the relative stability
of the drug-bound channel in the presence of each enanti-
omer. The values for AG were -6.16 and -7.27 kcal/mol
for S(-)-bupivacaine and R(+)-bupivacaine, respectively.
Thus, the stereoselectivity in hKvl.5 block corresponds to a
difference in free energy of 1.11 kcal/mol between R(+)-
bupivacaine and S(-)-bupivacaine blocked channels. This
could reflect a more stable interaction of the R(+)-enanti-
omer with the receptor. However, differences in potency
between both enantiomers was explained largely by their
different association rate constants, which were faster for
R(+)-bupivacaine. Because these drugs are enantiomers,
most properties are identical, including the free energy
associated with similar mirror image conformations. There-
fore, the difference in association rates suggests that the
S(-)-enantiomer needs to adopt a less favored conforma-
tion, i.e., 1.11 kcal/mol above that of the antipode of the
conformation in which R(+)-bupivacaine binds. Additional
studies, probably including molecular modeling, will be
needed to elucidate the detailed structural requirements for
stereoselectivity and binding of local anesthetic and antiar-
rhythmic drugs.
Practical implications regarding toxicity
Bupivacaine is a potent local anesthetic widely used for
long lasting regional local anesthesia (Strichartz and
Ritchie, 1987). In isolated cardiac tissues, racemic bupiva-
caine decreased intracardiac conduction velocity and wid-
ened the QRS complex of the electrocardiogram by inhib-
iting INa (Clarkson and Hondeghem, 1985; Wheeler et al.,
1988). Both in animal models and in humans, bupivacaine
prolonged the duration of the cardiac action potential
(Avery et al., 1984; Kasten and Martin, 1985; Scott et al.,
1989; Solomon et al., 1990) and the Q-Tc interval of the
ECG (Scott et al., 1989). This prolongation of the Q-Tc
interval occasionally can result in the development of a
polymorphic ventricular tachycardia similar to that seen in
torsades de pointes (Kasten and Martin, 1985). Therefore,
the electrical aspects of bupivacaine-induced cardiotoxicity
could be explained by its inhibition of both cardiac Na+ and
K+ channels. Moreover, the prolongation of the cardiac
action potential induced by their K+ channel block would
further enhance block of the inactivated state of the cardiac
Na+ channel. Because the R(+)-enantiomer has a higher
affinity for both the inactivated state of the sodium channel
and for hKvl.5 channels than S(-)-bupivacaine, the syner-
gistic interaction could explain the higher toxicity of the
R(+) enantiomer. Although mechanical failure may only be
apparent with very high plasma concentrations (Tucker and
Mather, 1975), a major cause of death with bupivacaine
appears to be ventricular fibrillation (Albright, 1979). Ad-
verse effects on both conductivity and contractility of myo-
cardium can be detected at much lower plasma bupivacaine
concentrations (1.22 ,ug/ml = 4.1 ,M) than those reported
at cardiotoxic levels, when more sensitive methods are used
(Scott et al., 1989). In fact, these authors showed that
cardiovascular changes can be detected before the clinical
symptoms will appear. Comparison of the cardiovascular
effects of S(-)-bupivacaine with those of the racemate in
male volunteers demonstrated a reduced cardiotoxicity of
S(-)-bupivacaine: no significant electrocardiographic ef-
fects were detected with S(-)-bupivacaine, whereas ra-
cemic bupivacaine induced both mechanical depression and
small but significant ECG alterations (Gristwood et al.,
1994). Moreover, the systemic disposition of racemic bupiv-
acaine is stereoselective in humans, resulting in a slower
elimination of the unbound R(+)-enantiomer (Burm et al.,
1994). Because the R(+)-enantiomer has a higher affinity
for both the inactivated state of the sodium channel and for
this cardiac potassium channel, the synergistic interaction
could explain the higher toxicity of the R(+) enantiomer.
Thus, in clinical practice S(-)-bupivacaine, which exhibits
a lower affinity for both Na+ and hKv1.5 channels, could be
a less cardiotoxic alternative to racemic bupivacaine. Obvi-
ously, further clinical studies will be needed to evaluate
whether this difference in biophysical properties between
both enantiomers has practical implications regarding safety
and toxicity.
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